BridgeMD
New treatment option for Non Small Cell Lung Cancer
Official title Concomitant Use of Radiotherapy and Integrated Exercise - Lung Cancer
ClinicalTrials.gov ID: NCT07489391
What this study is testing
- What it's testing
- Study objective and procedures The objective of CURIE-LC is to evaluate the feasibility (i.e., whether it is possible and safe) of carrying out a comprehensive exercise program during combined radiotherapy and chemotherapy in patients with lung cancer. The study will assess whether patients can adhere to the exercise program while receiving oncologic treatment and will explore its effects on physical fitness and quality of life.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histological diagnosis of non-small cell lung cancer (NSCLC) at stage II-III (locally advanced), unresectable/inoperable.
- Candidate for radical radiotherapy with concomitant chemotherapy, with or without maintenance Durvalumab.
- ECOG performance status ≤2 (or Karnofsky index ≥60).
- Ability to communicate adequately with the research team and to complete questionnaires and functional tests.
- Signed written informed consent after receiving detailed information about the study.
You likely can't join if
- Decompensated cardiorespiratory comorbidities that contraindicate moderate-intensity physical exercise:
- New York Heart Association (NYHA) class III-IV congestive heart failure or unstable angina.
- Recent myocardial infarction (\<6 months) or uncontrolled arrhythmias.
- Very severe chronic obstructive pulmonary disease (COPD) GOLD IV with recent exacerbations, permanent home oxygen therapy, or severe pulmonary...
- Severe physical or neurological limitations that prevent exercise.
- Absolute medical contraindications to inspiratory muscle training: unresolved pneumothorax, recent thoracic surgery (\<4 weeks), or active hemoptysis.
See the full eligibility criteria
- Histological diagnosis of non-small cell lung cancer (NSCLC) at stage II-III (locally advanced), unresectable/inoperable.
- Candidate for radical radiotherapy with concomitant chemotherapy, with or without maintenance Durvalumab.
- ECOG performance status ≤2 (or Karnofsky index ≥60).
- Ability to communicate adequately with the research team and to complete questionnaires and functional tests.
- Signed written informed consent after receiving detailed information about the study.
- Decompensated cardiorespiratory comorbidities that contraindicate moderate-intensity physical exercise:
- New York Heart Association (NYHA) class III-IV congestive heart failure or unstable angina.
- Recent myocardial infarction (\<6 months) or uncontrolled arrhythmias.
- Very severe chronic obstructive pulmonary disease (COPD) GOLD IV with recent exacerbations, permanent home oxygen therapy, or severe pulmonary hypertension.
- Severe physical or neurological limitations that prevent exercise.
- Absolute medical contraindications to inspiratory muscle training: unresolved pneumothorax, recent thoracic surgery (\<4 weeks), or active hemoptysis.
- Refusal or inability to understand/follow the program instructions (e.g., severe cognitive impairment, insurmountable language barrier).
The study team makes the final eligibility decision.
Where it's taking place
- Barcelona, Catalonia, Spain
- Pamplona, Navarre, Spain
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Barcelona, Catalonia, Spain; Pamplona, Navarre, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.